Arginine/asymmetric dimethylarginine ratio and cardiovascular risk factors in patients with predialytic chronic kidney disease
- 30 June 2011
- journal article
- Published by Elsevier BV in Clinical Biochemistry
- Vol. 44 (8-9), 642-646
- https://doi.org/10.1016/j.clinbiochem.2011.03.024
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Prediction of ESRD and Death Among People With CKD: The Chronic Renal Impairment in Birmingham (CRIB) Prospective Cohort StudyAmerican Journal of Kidney Diseases, 2010
- The beneficial effects of angiotensin-converting enzyme inhibitors on serum asymmetric dimethylarginine levels in the patients with cardiovascular diseaseInternational Journal of Cardiology, 2010
- Asymmetric Dimethylarginine and Mortality in Stages 3 to 4 Chronic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2009
- Asymmetrical Dimethylarginine in Renal Disease: Limits of Variation or Variation Limits?American Journal of Nephrology, 2007
- Health‐associated reference values for arginine, asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) measured with high‐performance liquid chromatographyScandinavian Journal of Clinical and Laboratory Investigation, 2007
- Molecular Mechanism for Elevation of Asymmetric Dimethylarginine and Its Role for Hypertension in Chronic Kidney DiseaseJournal of the American Society of Nephrology, 2006
- l-arginine improves endothelial function and reduces LDL oxidation in patients with stable coronary artery diseaseClinical Nutrition, 2005
- Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trialsVascular Medicine, 2005
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationThe New England Journal of Medicine, 2004
- Reduced plasma L-arginine in hypercholesterolaemiaThe Lancet, 1992